Illustration showing how miniature artificial protocells loaded with anti-microRNA-223 cargo can reprogram cancer-associated macrophages in larval and adult zebrafish leading them to be more pro-inflammatory and thus able to drive melanoma shrinkage
CREDIT: Paco Lopez Cuevas
Discovery demonstrates a new way to clear early stage pre-cancerous and even late-stage tumour cells
A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The University of Bristol-led discovery, published in Advanced Science today [31 October], demonstrates a new way to clear early stage pre-cancerous and even late-stage tumour cells.
Using miniature artificial capsules called protocells designed to deploy reprogramming cargoes that are taken up by inflammatory cells (white blood cells), the scientists show they were able to transform these cells into a state that makes them more effective at slowing down the growth and killing of melanoma cells. They showed that this was possible for both animal and human immune cells.
The study is the first to test the capacity of a protocell to deliver cargoes for reprogramming immune cells and offers a promising novel target for the development of cancer immunotherapies.
Paul Martin, Professor of Cell Biology in the School of Biochemistry at the University of Bristol and one of the study’s lead authors explained what happens when our immune system comes into contact with cancer cells: “Our immune cells have a surveillance capacity which enables them to detect pre-cancerous cells arising at any tissue site in the body. However, when immune cells encounter cancer cells they are often subverted by the cancer cells and instead tend to nourish them and encourage cancer progression. We wanted to test whether it might be possible to reprogramme our immune system to kill these cells rather than nurture them.”
First, the team tested the proof of concept in zebrafish larvae which are used due to their translucency, allowing researchers to watch inflammatory immune cells interact with cancer cells in ways not possible in our own tissues.
Protocells loaded with anti-miR223 molecules that bind to and interfere with signalling machinery in the inflammatory immune cells and work by effectively prolonging their pro-inflammatory state, were shown to drive altered immune cell-cancer cell interactions, slowing the growth of cancerous cells and driving increased tumour cell death in the larvae.
To find out whether this approach might be upscaled as a feasible therapeutic strategy for shrinking larger, more established, and growing cancers, the experiment was repeated in adult fish with tailfin melanomas, showing this approach significantly inhibited melanoma cell growth.
To fully investigate the feasibility of using protocells to deliver ‘reprogramming’ anti-miR223 cargoes in humans, the experiment was conducted again using an in vitro assay with primary human immune cells from the Toye lab, also in Bristol’s School of Biochemistry. Results from this experiment demonstrated that the protocells were able to effectively deliver and reprogramme human immune cells toward a more persistent pro-inflammatory and potentially anti-cancer state.
Professor Stephen Mann from Bristol’s School of Chemistry and the Max Planck Bristol Centre for Minimal Biology added: “Our results highlight the therapeutic benefits of harnessing host immunity to eradicate cancers and demonstrate the feasibility of using protocells to deliver cargoes for reprogramming innate immune cells. While our experiments in zebrafish are early pre-clinical studies, our results indicate that the same is possible for human immune cells, at least in vitro, and can be similarly reprogrammed to supress cancer growth.”
Original Article: Reprogramming of immune cells shown to fight off melanoma
More from: University of Bristol
The Latest Updates from Bing News
Go deeper with Bing News on:
Reprogramming immune cells
- People amazed at 'wild' video of immune cell fighting a highly aggressive deadly cancer cell and winning
T-cells are a special form of white blood cells that the immune system uses to help protect the body from illnes and help defend it against cancer. As perfectly documented in the video, the T-cells ...
- Immune Cells Stay on Standby to Defend Immune System
Defense cells are constantly stimulated by healthy tissue to keep them vigilant and ready to respond to pathogens.
- Immune Cells Carry a Long-Lasting “Memory” of Early-Life Pain
Research in mice indicates that focusing on genetic alterations in macrophage cells could be beneficial. Recent research increasingly suggests that the human body can retain memories of pain from ...
- Bacteria in the intestine that change in response to inflammation could have an impact on our immune system
Gut bacteria have emerged as a focal point of scientific exploration, with their intricate roles in our metabolism, nutrition, and overall health coming into sharp focus. New research from the ...
- Researchers develop a new way to safely boost immune cells to fight cancer
Researchers explore a cancer immunotherapy treatment that involves activating the immune cells in the body and reprogramming them to attack and destroy cancer cells. This therapeutic method frequently ...
Go deeper with Bing News on:
Inhibiting melanoma cell growth
- Component of keto diet plus immunotherapy may reduce prostate cancer
Adding a pre-ketone supplement—a component of a high-fat, low-carb ketogenic diet—to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer, researchers ...
- Can vitamin D help fight cancer?
When his colleague Evangelos Giampazolias, now at the Cancer Research UK Manchester Institute, discovered that switching off the gene which provides instructions to make the aptly named vitamin ...
- Vitamin D may balance gut microbiome to give cancer immunotherapy a boost
A new study in mice found that dietary vitamin D plays a role in balancing the gut microbiome and improving the way cancer immunotherapy works to fight tumors.
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –– Additional data from the Phase 3 DeFi trial of ...
- AstraZeneca: What The Market's Missing
AstraZeneca has a strong pipeline, recent approvals, and a series of acquisitions that offer promising prospects. Read why AZN stock is a Buy.